226330 — Syntekabio Income Statement
0.000.00%
Last trade - 00:00
- KR₩108bn
- KR₩96bn
- KR₩123m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 461 | 610 | 317 | 244 | 123 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5,656 | 7,707 | 9,183 | 12,031 | 13,075 |
Operating Profit | -5,194 | -7,098 | -8,866 | -11,787 | -12,951 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22,966 | -6,488 | -14,803 | -4,506 | -11,398 |
Provision for Income Taxes | |||||
Net Income After Taxes | -22,966 | -6,488 | -14,803 | -4,506 | -11,398 |
Net Income Before Extraordinary Items | |||||
Net Income | -22,966 | -6,488 | -14,803 | -4,506 | -11,398 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -22,966 | -6,488 | -14,803 | -4,506 | -11,398 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2,295 | -490 | -1,101 | -334 | -749 |
Dividends per Share |